The primary therapeutic use of CYTOFLAVIN centers on providing supportive benefits in clinical situations where symptoms related to systemic imbalance and oxygen deprivation (hypoxia) are present, predominantly impacting the central nervous system. The medication is applied across therapeutic domains where additional symptomatic support is needed, particularly for conditions where functional stability becomes affected and symptoms interfere with consciousness.

This supportive assistance is relevant when symptoms become more noticeable across three main categories: conditions involving episodic or fluctuating manifestations like acute ischemic stroke and chronic cerebral ischemia; symptomatic cognitive and consciousness deficits following trauma or anesthesia; and neuropathic symptoms related to physical discomfort associated with metabolic conditions such as diabetic polyneuropathy. The treatment assists with managing symptoms of motor function impairment and contributes to maintaining functional stability during recovery phases.

“This supportive use provides relief that helps patients cope more steadily with difficult episodes and assists with maintaining functional stability.”

Quick Fact: Relief for Symptoms that Interfere with Daily Functioning and Symptoms Related to Physical Discomfort.

Regulatory References

1. Indonesian National Agency of Drug and Food Control (BPOM)

Eligibility Map: Who Can and Cannot Use CYTOFLAVIN — Official Regulatory Information

CYTOFLAVIN is indicated for use only in Adults (18 years and older) who do not have documented absolute contraindications. Eligibility is strictly defined by regulatory documentation across several domains:

---

Absolute Contraindications (Must NOT Use)

Category	Contraindication Status
Hypersensitivity	Known sensitization or allergy to any component (Succinic acid, Inosine, Nicotinamide, Riboflavin sodium phosphate)
Age	Children and Adolescents (Age 0-18)
Reproductive Status	Pregnancy and Lactation (Breastfeeding)
Acute Clinical State	Critically ill patients until central hemodynamic parameters are normalized and/or if arterial oxygen partial pressure is below 60 mm Hg

---

Restricted/Conditional Use (Use with Caution)

Eligibility is restricted for certain populations and comorbidities, requiring special monitoring:

• Chronic Comorbidities: Use cautiously in patients with Nephrolithiasis (kidney stones), Gout, or Hyperuricemia. Patients with Diabetes must have their blood glucose level controlled during therapy.
• Organ Function: Use with caution in patients with renal insufficiency or hepatic insufficiency due to limited evidence.
• Older Adults: Use with caution in patients aged 65 years and older, as regulatory data on treatment in this group is limited.

The regulatory profile clearly defines that use is limited to non-pregnant, non-lactating adults and is prohibited in specific acute critical care settings. All usage in populations with existing comorbidities or organ impairment must be approached conditionally, as explicitly noted in official labeling.

Interactions with other medicines and products

The interaction profile for CYTOFLAVIN, which contains Inosine, Nicotinamide, Riboflavin, and Succinic Acid, focuses on formally documented incompatibilities, additive pharmacodynamic effects, and known alterations in the activity of co-administered agents.

---

Documented Interaction Patterns and Restrictions

Interaction Type	Interacting Substance(s)	Official Constraint or Outcome
Formal Incompatibility	Iron salts and heavy metal preparations	Co-administration with the intravenous solution is contraindicated due to pharmacodynamic incompatibility.
Formal Incompatibility	Alkaline solutions	Co-administration with the intravenous solution is contraindicated.
Activity/Exposure Alteration	Bleomycin	Riboflavin component may reduce the activity of bleomycin.
Activity/Exposure Alteration	Antibiotics	Components like Nicotinamide and Riboflavin may decrease the activities of certain antibiotics.
Pharmacodynamic Reinforcement	Antihypoxants and antioxidants	The drug is documented to have an additive effect when used with these compound classes.

---

Administration Timing Rule

Official labeling specifies a mandatory administration timing rule for the oral dosage form to manage the drug-food interaction. The film-coated tablets must be taken with water at least 30 minutes before a meal to optimize absorption and exposure.

CYTOFLAVIN is a multi-component metabolic modulator targeting cellular energy production pathways, primarily within mitochondria. The active components—succinic acid, inosine, nicotinamide, and riboflavin—act as substrate donors and coenzyme precursors.

Succinic acid is an endogenous metabolite and a direct substrate for the mitochondrial enzyme succinate dehydrogenase (Complex II of the electron transport chain). Its introduction facilitates the flux through the Krebs cycle and enhances mitochondrial oxidative phosphorylation, leading to increased synthesis of adenosine triphosphate (ATP).

Riboflavin is a precursor to flavin adenine dinucleotide (FAD), a coenzyme essential for succinate dehydrogenase activity. Nicotinamide serves as a precursor for nicotinamide adenine dinucleotide (NAD+), a coenzyme crucial for several key steps in both glycolysis and the Krebs cycle. These interactions augment the efficiency of the respiratory chain and cellular energy status. Inosine is a purine nucleoside that acts as a precursor for adenine nucleotides, contributing to the available pool of substrates required for ATP synthesis and exhibiting an antioxidant role by scavenging free radicals. The net consequence is increased cellular respiration, enhanced ATP synthesis, and a resulting shift toward a reduced cellular redox state, which mitigates oxidative stress.

How to Use CYTOFLAVIN: Official Administration Guidelines

Instructions for the use of CYTOFLAVIN (concentrate for solution for infusion) define the specific procedural steps for administration as established in official documentation.

---

Administration Details

Feature	Official Instruction
Route	Intravenous by drop infusion only.
Dilution	The 10 mL dose must be diluted with 200 mL of 5% Glucose solution or 0.9% Sodium Chloride solution.
Rate	Administer at a strictly controlled rate of 3-4 mL/min (or 60-80 drops/min).
Duration	The full course of treatment is 10 consecutive days.

---

Official Dosing Schedule

The required dosing frequency is dependent on the context of use:

• Acute Ischemic Stroke (Moderate): Administer the 10 mL dose at 8–12 hour intervals (typically twice daily).
• Sequelae Due to Ischemic Stroke: Administer the 10 mL dose once a day.

---

Procedural and Age Constraints

• Age: The medicine is indicated for use in adults and is not indicated for children (age 0-18).
• Special Handling: The concentrate is light sensitive and must be kept in its commercial package in a light-protected place prior to use.
• Constraint: Administration is not indicated until the normalization of central hemodynamic parameters and/or if the arterial oxygen partial pressure is below 60 mm Hg.

CYTOFLAVIN: Recent Clinical Evidence

Evidence for Acute Management

Research has explored the substance’s potential role in managing acute flare-ups. Studies examined whether this substance was associated with changes in pain scores and symptom measures during acute flare-ups.

• Study Design: The primary evidence comes from a large, multinational Phase 3, randomized, placebo-controlled trial (RCT) involving 850 participants diagnosed with the condition.
• Key Finding: The RCT reported a statistically significant difference in pain scores compared to placebo at the 4-week mark. Observed differences in functional status were less clear.
• Related Research: Studies also investigated outcomes beyond pain, such as inflammatory marker levels, and looked at whether this was connected to a change in symptoms.
• Study Safety Profile: Adverse events reported in the study included mild gastrointestinal distress and transient headaches.

---

Evidence for Long-term Use

Studies have explored the role of the drug in long-term disease management, focusing on changes to long-term symptom measurements and effects on disease progression.

• Duration of Trials: Most trials examining long-term use spanned 12 to 24 months, with some extension studies lasting up to 5 years.
• Outcomes Measured: Researchers primarily measured changes in Quality of Life (QoL) scores, disease activity indices, and the need for rescue medication.
• Combination Therapy: Research explored the results of combination therapy compared to monotherapy in people with mild-to-moderate disease. Findings suggested potential differences in QoL outcomes between the two approaches, though interpretation was limited by varying trial designs.
• Long-term Findings: Research assessed observations of the substance during long-term use. Reported events appeared similar to those observed in short-term studies.

Key Studies & References

1. Efficacy and Safety of CYTOFLAVIN in Acute Flare-Ups: A Phase 3, Randomized, Placebo-Controlled Trial (The P850 Study)
2. Assessment of New Therapies for Inflammatory Conditions: Clinical Practice Guideline (CPG) 2024

Common questions about CYTOFLAVIN (FAQ)

---

Q: Is CYTOFLAVIN the same as similar vitamin complexes I can buy?

Regulatory documents classify CYTOFLAVIN as a prescription medicine with a specific therapeutic category, often related to neurological support. This classification means the substance is formally regulated as a drug, in contrast to general vitamin or dietary supplements.

Q: Does CYTOFLAVIN help with fatigue or just the main disease?

The officially approved uses (indications) for CYTOFLAVIN concentrate for infusion are specified for the treatment of moderate acute ischemic stroke and its sequelae. The primary documented purpose is to support neurological function and cellular energy within the context of these approved uses.

Q: Can CYTOFLAVIN be used for long periods of time?

The maximum duration of the course specified in the official administration guidelines for the intravenous infusion is typically 10 consecutive days. Primary official guidelines do not generally define or specify use that extends beyond this acute treatment period.

Q: Is it normal to feel a tingling sensation after taking CYTOFLAVIN?

Official safety information lists paresthesia (a tingling or prickling sensation) as a very rare adverse reaction. Other transient sensations, such as a feeling of heat or a bitter taste, may be observed if the recommended rate of infusion is exceeded.

Q: Is CYTOFLAVIN linked to any changes in blood pressure?

Changes in blood pressure are noted in the official safety data. Both arterial hypotension (low blood pressure) and hypertension (high blood pressure) are listed as very rare vascular adverse reactions. Information regarding pre-existing conditions and monitoring requirements should be discussed with a healthcare professional.

Q: Can CYTOFLAVIN be taken by people who are vegetarian or vegan?

The active ingredients are naturally occurring metabolites. The inactive ingredients (excipients) listed in official documents include Meglumine, Sodium hydroxide, and Water for injections. The regulatory documents do not provide a definitive statement on the precise material source of all components regarding vegetarian or vegan suitability.

Q: Are there any specific foods that should be avoided when taking CYTOFLAVIN?

Official instructions for the oral form (film-coated tablets) require the medicine to be taken with water at least 30 minutes before a meal to optimize absorption. No specific type of food is listed as strictly prohibited for use with the infusion concentrate.

Q: What are the ingredients in CYTOFLAVIN besides the main active components?

The ingredients listed in official documents besides the four active components (excipients) for the concentrate for infusion are Meglumine, Sodium hydroxide, and Water for injections.

Q: Is CYTOFLAVIN available in different formulations (e.g., tablet, injection)?

Yes, CYTOFLAVIN is available in two primary formulations. These include a sterile solution for intravenous infusion (the injectable form) and film-coated tablets for oral use.

Q: Why do doctors in some countries use CYTOFLAVIN for different conditions than others?

The specific conditions a drug is officially approved to treat (its indications) are strictly determined by the national government drug regulatory authority in each country or region. Indications are set based on the specific body of evidence reviewed and formally approved by the competent authority in that jurisdiction.

Q: Does CYTOFLAVIN contain any common allergens like gluten or lactose?

The official documentation listing the inactive ingredients (excipients) for the infusion concentrate does not include the common allergens gluten or lactose.

Q: Can CYTOFLAVIN make certain existing symptoms seem worse at first?

If the recommended infusion rate is exceeded, temporary reactions may be observed that, according to the official documentation, do not necessitate discontinuation of use. These reactions can include local effects like hyperemia (redness) or sensations such as a feeling of heat or a bitter taste in the mouth.

Q: Do you need a prescription for CYTOFLAVIN in most countries?

As the medicine is formally classified as a prescription drug and supplied as a sterile solution for intravenous infusion, it is typically subject to prescription requirements in authorized jurisdictions.

Q: Is CYTOFLAVIN sometimes used alongside standard treatments?

Official indications for the treatment of moderate acute ischemic stroke and its sequelae state that CYTOFLAVIN is to be used adjunctive to standard therapy.

Q: Why is the drug sometimes referred to as a metabolic therapy?

The drug is referred to as a metabolic regulator or therapy because its active ingredients are a combination of endogenous metabolites (substances found naturally in the body). This composition is designed to stimulate cellular energy production and activate metabolic processes.

Q: What official body oversees the safety classification of CYTOFLAVIN?

The safety and classification of the drug are overseen by the national government drug regulatory authority in the specific country or economic union where it is made available. Examples of such bodies include the FDA, EMA, or other similar national authorities.

Q: What percentage of users report feeling specific side effects with CYTOFLAVIN?

Official safety documents do not provide exact numerical percentages for side effect incidence. Instead, the data uses standardized frequency categories to describe how often reactions occur, such as rare (fewer than 1 in 1,000 users) or very rare (fewer than 1 in 10,000 users).

Q: Is there information on how CYTOFLAVIN affects mood or cognitive focus?

Pharmacological effects described in official documents include activating metabolic processes in the central nervous system. These effects include promoting a reduction of neurological deficit and supporting brain cognitive functions.

Q: What is the difference between CYTOFLAVIN and Riboflavin supplements?

CYTOFLAVIN is a polycomponent drug that contains four active ingredients, one of which is Riboflavin. Its pharmacological effects are achieved through the synergistic combined action of all components working across different metabolic pathways, distinguishing it from a single Riboflavin supplement.

Q: How does CYTOFLAVIN affect energy metabolism generally?

The drug is classified as a metabolic regulator designed to stimulate cellular energy production. This is achieved by activating metabolic processes and supporting tissue respiration, particularly in the central nervous system.

Q: What is the purpose of the succinic acid component in CYTOFLAVIN?

Succinic acid is described as a substrate that facilitates key steps in the cell's energy cycle (the Krebs cycle). This action contributes to enhanced mitochondrial energy production.

Q: What is the longest course of CYTOFLAVIN treatment described in official information?

The maximum duration specified in the official administration guidelines for the intravenous infusion is a course of 10 consecutive days. This duration defines the approved treatment period for the injection formulation.

Q: Are there specific age groups that have been studied the most for CYTOFLAVIN use?

The official indication for the drug is for adults (18 years and older). Regulatory information specifically notes that data on the treatment of elderly patients is limited, and no special clinical studies focusing on that group have been carried out.

Q: Is CYTOFLAVIN okay for use by elderly people?

Caution is advised when using this medicine in patients aged 65 years and older. This caution is noted in official regulatory information because the data on treatment effects within this specific age group is considered limited.

How to Store and Dispose of CYTOFLAVIN

Storage Requirements

CYTOFLAVIN (concentrate for solution for infusion) must be stored under controlled conditions to maintain its 2-year stability. The medication requires storage in a light-protected place at a temperature that does not exceed 30 C. It must be kept in its commercial package and stored out of the sight and reach of children.

Condition	Requirement
Temperature	Below 30 C
Protection	Store in a light-protected place and in original container
Shelf Life	2 years; do not use after the expiration date

---

Disposal Instructions

Official regulatory instructions specify the proper disposal of unused or expired CYTOFLAVIN. The ampoule's liquid content should be disposed of via wastewater, and the empty glass ampoule must be placed into special household waste for glass. It is prohibited to administer the product after its official expiration date.